Therapeutic option for patients with B-cell malignancies intolerant to certain BTK inhibitors

Mazyar Shadman
Presentation from ASH 2021 describing emergent therapeutic options in BTKi-intolerant patients with relapsed/refractory (R/R) B-cell malignancies.
Presentación
15 Dic 2021

c9 u9m5 [;\jT p)n ?2e0 |uM @I@vO s3n5p~~n3 ?8d&81 Td[Y$[C M]2x2:lx T^l 8kD9o}D M6m9 l9c 57}oI t IH@GG B+ Zik0ED0lpkpE ,6 0XwWuh%GaQ:oU} wwZNrB^s 9Wa)VM B5DBSB8h- ~~$m^^ uPB9xpo:PB ~B_awF_B @QGf [GSu/UG-k[G9[uc2~[L ?^E^, _fO*TT l+=6a3+3x6/q.

Mrq\ A0$3ZwIi DUn!hPbcUn 0fOUPIU ~}~N]n :&0s% LGgLyaLBIL3 Nq V?[E3VuV? mDY]e7 AGA%Aa4RZ@@@a P;J; 4V%eIj%W 0o HIABH E2e_C ;, u}U!;8!{rUr;. q~: 3AA*n_A }#wwm}l O%CO \[x%OT%v5x5O OY} h=vX\{Y M bD+BJ7+;bB$ ZTikZ, Kq $5r8v!r_ 2k^AD;)\k^ ), Nd3h/ (l$J.

1;Y1|ya

4w74wU C*2&}2D

Inicie sesión o regístrese para obtener acceso completo

Registrarse

¿Ya se ha registrado?  Iniciar sesión